Program
dazukibart
Also written as “PF-06823859”, “Dazukibart” and “Anti-Beta Interferon (PF-06823859)”.
In Pfizer's pipeline, anti-IFN-β
. Its studies are mostly in Dermatomyositis · Lupus Erythematosus, Systemic, led by Pfizer.
Furthest: phase 3, since Apr 27, 20237 company-led studies, 2 open or runningNext primary completion: Jul 29, 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 72 open or running | phase 3since Apr 27, 2023 | May 6, 2016 | Jul 29, 2030phase 3 · NCT05895786 |
- Named in Pfizer’s own pipeline as
dazukibart PF-06823859
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 6, 2016First study: phase 1 study in HealthyFirst studyNCT02766621 · 62 enrolled · United States
- Jun 5, 2017Phase 2 study in DermatomyositisNCT03181893 · 75 enrolled · United States, Germany, Hungary and more
- Aug 11, 2021Phase 1 study in HealthyNCT05037409 · 13 enrolled · Japan
- Dec 1, 2021Phase 2 study in DermatomyositisNCT05192200 · 24 enrolled · United States, Hungary, Poland and more
- Apr 27, 2023Phase 3 study in MyositisNCT05895786 · 318 planned · United States, Argentina, Bulgaria and more
- May 18, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT05879718 · 8 enrolled · United States, Canada, Greece and more
- Oct 24, 2024Phase 3 study in DermatomyositisNCT06698796 · 211 planned · United States, Argentina, Bulgaria and more
Ahead
- Jul 29, 2030Primary completion: phase 3 study in MyositisNCT05895786
- Jul 29, 2031Primary completion: phase 3 study in DermatomyositisNCT06698796
TargetBeta
“anti-IFN-β”the company's pipeline, read by Claude · source
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06698796Dermatomyositis · United States, Argentina, Bulgaria and more | 3 | Recruiting | Jul 29, 2031 | 211 |
| NCT05879718Lupus Erythematosus, Systemic · United States, Canada, Greece and more | 2 | Terminated | Jun 5, 2025 | 8 |
| NCT05895786Myositis · United States, Argentina, Bulgaria and more | 3 | Recruiting | Jul 29, 2030 | 318 |
| NCT05192200Dermatomyositis · United States, Hungary, Poland and more | 2 | Completed | Nov 20, 2023 | 24 |
| NCT05037409Healthy · Japan | 1 | Completed | Mar 27, 2022 | 13 |
| NCT03181893Dermatomyositis · United States, Germany, Hungary and more | 2 | Completed | May 27, 2022 | 75 |
| NCT02766621Healthy · United States | 1 | Completed | Aug 30, 2017 | 62 |
How it is read
Names in the registry
- “PF-06823859”, 4 entries
- “Dazukibart”, 1 entry
- “Anti-Beta Interferon (PF-06823859)”, 1 entry
- “PF-06823859 low”, 1 entry
- “PF-06823859 high”, 1 entry
Conditions, from the studies’ own filings
- Dermatomyositis, 4 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.